David T Yang

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. pmc Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
    David T Yang
    Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, USA
    Mol Cancer 7:40. 2008
  2. pmc Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma
    David T Yang
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, USA
    Appl Immunohistochem Mol Morphol 19:62-9. 2011
  3. pmc Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)
    Julie E Chang
    University of Wisconsin, Madison, WI
    Blood 123:1665-73. 2014
  4. pmc Immunohistochemical evaluation of MYC expression in mantle cell lymphoma
    Matthew J Oberley
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA
    Histopathology 63:499-508. 2013
  5. doi request reprint A unique CD4+ large granular lymphocytosis occurring in patients treated with tumor necrosis factor α inhibitors: report of 2 cases
    Adam Covach
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI
    Hum Pathol 46:1237-41. 2015
  6. pmc TPL2 kinase regulates the inflammatory milieu of the myeloma niche
    Chelsea Hope
    Department of Medicine, Division of Hematology Oncology, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI University of Wisconsin Carbone Cancer Center, Madison, WI
    Blood 123:3305-15. 2014
  7. pmc Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
    Anne M Traynor
    Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lung Cancer 81:138-41. 2013
  8. pmc VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
    Julie E Chang
    Department of Medicine, School of Medicine and Public Health, The UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53705, USA
    Br J Haematol 155:190-7. 2011

Collaborators

  • Shigeki Miyamoto
  • Brad Kahl
  • Ranjana H Advani
  • Sangbum Choi
  • Ravi Salgia
  • Adam M Petrich
  • Tien Hoang
  • Anne M Traynor
  • Deric L Wheeler
  • Julie E Chang
  • Adam Covach
  • Saurabh A Rajguru
  • Chelsea Hope
  • Matthew J Oberley
  • Kyungmann Kim
  • Catherine P Leith
  • Hailun Li
  • Marta Chesi
  • Jeffrey L Jensen
  • P Leif Bergsagel
  • Fotis Asimakopoulos
  • Sandra J Horning
  • Ioanna Maroulakou
  • Elisabeth M Paietta
  • Mitchell R Smith
  • Natalie Callander
  • Peiman Hematti
  • Randy D Gascoyne
  • Jaehyup Kim
  • Erika Heninger
  • Ellen Hebron
  • Samuel J Ollar
  • Catherine Leith
  • Chong Zhang
  • Jennifer Laffin
  • Gene R Shaw
  • Kreg M Grindle
  • Craig Kanugh
  • Michael Volk
  • Jae E Werndli
  • Jules Blank
  • Jens C Eickhoff
  • Leslie A Gilbert
  • Thomas A McFarland
  • Eric S Rogers
  • Natalie S Callander
  • Michael S Huie
  • Walter L Longo
  • Christopher Peterson

Detail Information

Publications8

  1. pmc Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
    David T Yang
    Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, USA
    Mol Cancer 7:40. 2008
    ..While MCL cells have been shown to harbor constitutive NF-kappaB activity, what fraction of this activity in primary MCL samples is sensitive or resistant to inhibition by bortezomib remains unclear...
  2. pmc Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma
    David T Yang
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, USA
    Appl Immunohistochem Mol Morphol 19:62-9. 2011
    ....
  3. pmc Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)
    Julie E Chang
    University of Wisconsin, Madison, WI
    Blood 123:1665-73. 2014
    ..This study was registered at www.clinicaltrials.gov as #NCT00433537. ..
  4. pmc Immunohistochemical evaluation of MYC expression in mantle cell lymphoma
    Matthew J Oberley
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA
    Histopathology 63:499-508. 2013
    ..To assess the validity and potential clinical utility of evaluating MYC expression by immunohistochemistry (IHC) in mantle cell lymphoma (MCL)...
  5. doi request reprint A unique CD4+ large granular lymphocytosis occurring in patients treated with tumor necrosis factor α inhibitors: report of 2 cases
    Adam Covach
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI
    Hum Pathol 46:1237-41. 2015
    ....
  6. pmc TPL2 kinase regulates the inflammatory milieu of the myeloma niche
    Chelsea Hope
    Department of Medicine, Division of Hematology Oncology, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI University of Wisconsin Carbone Cancer Center, Madison, WI
    Blood 123:3305-15. 2014
    ..Our results highlight a TLR2/6-dependent TPL2 pathway as novel therapeutic target acting nonautonomously through macrophages to control myeloma progression. ..
  7. pmc Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
    Anne M Traynor
    Department of Medicine and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Lung Cancer 81:138-41. 2013
    ..We sought to determine if protein expression of nEGFR is prognostic in early stage non-small cell lung cancer (NSCLC)...
  8. pmc VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study
    Julie E Chang
    Department of Medicine, School of Medicine and Public Health, The UW Carbone Cancer Center, University of Wisconsin, Madison, WI 53705, USA
    Br J Haematol 155:190-7. 2011
    ..The observed 3-year PFS and OS with VcR-CVAD in MCL were comparable to reported outcomes with more intensive regimens. A cooperative group trial (E1405) is attempting to replicate these promising results...